Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552

Active Not RecruitingPhase 2, Phase 3

Sponsor: Hoffmann-La Roche

Conditions: Non-Small Cell Lung Cancer

Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin

Countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
* Measurable disease
* Adequate recovery from most recent systemic or local treatment for cancer
* Adequate organ function
* Life expectancy greater than or equal to (\>/=) 12 weeks
* For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception

Exclusion Criteria:

* Inability to swallow oral medication
* Women who are pregnant or lactating
* Symptomatic, untreated CNS metastases
* History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
* Known active or uncontrolled human immunodeficiency virus (HIV) infection
* Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
* Inability to comply with other requirements of the protocol
Locations (164)
  • Sacramento, California, United States
  • Denver, Colorado, United States
  • Fort Myers, Florida, United States
  • St. Petersburg, Florida, United States
  • Lexington, Kentucky, United States
  • Las Vegas, Nevada, United States
  • Lebanon, New Hampshire, United States
  • New York, New York, United States
  • The Bronx, New York, United States
  • Portland, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Chattanooga, Tennessee, United States
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Ciudad Autonoma Buenos Aires, Argentina
  • St Leonards, New South Wales, Australia
  • Chermside, Queensland, Australia
  • Kurralta Park, South Australia, Australia
  • Brussels, Belgium
  • Brussels, Belgium
  • Leuven, Belgium
  • Ijuí, Rio Grande do Sul, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • São Paulo, São Paulo, Brazil
  • Rio de Janeiro, Brazil
  • Edmonton, Alberta, Canada
  • Winnipeg, Manitoba, Canada
  • Barrie, Ontario, Canada
  • Brampton, Ontario, Canada
  • London, Ontario, Canada
  • + 134 more on CT.gov